Reblozyl
FDA approves BMS’s Reblozyl for treatment of anaemia in adults with lower-risk MDS
August 30, 2023Research and Development FDA, Haematology, Reblozyl, anaemia, bristol myers squibb, myelodysplastic syndromes
Bristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has approved Reblozyl (luspatercept-aamt) for the …
Canadian approval for Reblozyl for transfusion-dependent anaemia in beta-thalassemia patients
September 29, 2020Manufacturing and Production, Sales and Marketing BMS, Canada, Reblozyl
Bristol Myers Squibb and Acceleron have managed to secure regulatory approval in Canada for Reblozyl (luspatercept) for the treatment of …
Positive CHMP opinion for BMS and Acceleron’s Reblozyl in transfusion-dependent anaemia sub-populations
May 1, 2020Medical Communications, Sales and Marketing Acceleron, Bristol-Myers Squibb, EU, Reblozyl
Bristol Myers Squibb and Acceleron Pharma’s Reblozyl (luspatercept) has secured a positivr opinion from the European Medicines Agency’s Committee for Medicinal …
FDA approval for BMS and Acceleron’s Reblozyl to reduce red blood cell transfusion dependence
April 6, 2020Manufacturing and Production, Sales and Marketing BMS, FDA, Reblozyl, pharma
The FDA has given the regulatory thumbs-up in the US of Reblozyl (luspatercept-aamt), the “first and only erythroid maturation agent” …
Celgene and Acceleron’s Reblozyl secures FDA approval for anaemia in beta thalassaemia
November 11, 2019Sales and Marketing Acceleron, Celgene, Reblozyl, beta thalassaemia, pharma
The FDA has moved to authorise Celgene and Acceleron Pharma’s Reblozyl (luspatercept-aamt) in the treatment of anaemia associated with the …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
